crabsallover highlights, key points, comments / links.
Kashfi et al coupled oxynitroxy and aryl sulphur moieties to aspirin to give NOSH1 which had, compared to aspirin; improved inflammation properties, reduced gastrointestinal bleeding and increased aspirins potency to prevent and reduce colon and other cancers.
References:
CGS1) New Scientist, 10 March 2012 http://www.newscientist.com/article/dn21543-gasfilled-aspirin-is-a-potent-anticancer-drug.html (accessed 15th March 2012)
CGS2) Kodela, R., Chattopadhyay, M., Kashfi, K., ‘NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals’, ACS Med. Chem. Lett., 2012, 3, pp. 257-262
CGS3) in press: Chattopadhyay, M., Kodela, R.,, Olson, K. R., Kashfi, K., 'NOSH–aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model', Biochem. Biophys. Res. Commun., 2012, doi:10.1016/j.bbrc.2012.02.051
Kashfi et al coupled oxynitroxy and aryl sulphur moieties to aspirin to give NOSH1 which had, compared to aspirin; improved inflammation properties, reduced gastrointestinal bleeding and increased aspirins potency to prevent and reduce colon and other cancers.
Fig.1: Chris Street, OU S827, March 2012 |
Fig.2: Chris Street, OU S827, March 2012 |
References:
CGS1) New Scientist, 10 March 2012 http://www.newscientist.com/article/dn21543-gasfilled-aspirin-is-a-potent-anticancer-drug.html (accessed 15th March 2012)
CGS2) Kodela, R., Chattopadhyay, M., Kashfi, K., ‘NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals’, ACS Med. Chem. Lett., 2012, 3, pp. 257-262
CGS3) in press: Chattopadhyay, M., Kodela, R.,, Olson, K. R., Kashfi, K., 'NOSH–aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model', Biochem. Biophys. Res. Commun., 2012, doi:10.1016/j.bbrc.2012.02.051
No comments:
Post a Comment